American Journal of Kidney Diseases
Volume 55, Issue 5 , Pages 824-834, May 2010

Early Urinary Markers of Diabetic Kidney Disease: A Nested Case-Control Study From the Diabetes Control and Complications Trial (DCCT)

  • Elizabeth F.O. Kern, MD, MS

      Affiliations

    • Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH
    • Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH
    • Corresponding Author InformationAddress correspondence to Elizabeth F. O. Kern, MD, MS, Department of Medicine/Endocrinology/BRB, Case Western Reserve University, 10900 Euclid Ave, Cleveland, OH 44106-4951
  • ,
  • Penny Erhard, BS

      Affiliations

    • Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH
  • ,
  • Wanjie Sun, MS

      Affiliations

    • The Biostatistics Center, George Washington University, District of Columbia, WA
  • ,
  • Saul Genuth, MD

      Affiliations

    • Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH
    • The Biostatistics Center, George Washington University, District of Columbia, WA
  • ,
  • Miriam F. Weiss, MD

      Affiliations

    • Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH
    • Renal Replacement, LLC, Lyndhurst, OH

Received 12 May 2009; accepted 12 November 2009. published online 08 February 2010.

Background

Urinary markers were tested as predictors of macroalbuminuria or microalbuminuria in patients with type 1 diabetes.

Study Design

Nested case-control of participants in the Diabetes Control and Complications Trial (DCCT).

Setting & Participants

87 cases of microalbuminuria were matched to 174 controls in a 1:2 ratio, while 4 cases were matched to 4 controls in a 1:1 ratio, resulting in 91 cases and 178 controls for microalbuminuria. 55 cases of macroalbuminuria were matched to 110 controls in a 1:2 ratio. Controls were free of micro-/macroalbuminuria when their matching case first developed micro-/macroalbuminuria.

Predictors

Urinary N-acetyl-β-d-glucosaminidase (NAG), pentosidine, advanced glycation end product (AGE) fluorescence, and albumin excretion rate (AER).

Outcomes

Incident microalbuminuria (2 consecutive annual AERs > 40 but ≤ 300 mg/d) or macroalbuminuria (AER > 300 mg/d).

Measurements

Stored urine samples from DCCT entry and 1-9 years later when macro- or microalbuminuria occurred were measured for the lysosomal enzyme NAG and the AGE pentosidine and AGE fluorescence. AER and adjustor variables were obtained from the DCCT.

Results

Submicroalbuminuric AER levels at baseline independently predicted microalbuminuria (adjusted OR, 1.83; P < 0.001) and macroalbuminuria (adjusted OR, 1.82; P < 0.001). Baseline NAG excretion independently predicted macroalbuminuria (adjusted OR, 2.26; P < 0.001) and microalbuminuria (adjusted OR, 1.86; P < 0.001). Baseline pentosidine excretion predicted macroalbuminuria (adjusted OR, 6.89; P = 0.002). Baseline AGE fluorescence predicted microalbuminuria (adjusted OR, 1.68; P = 0.02). However, adjusted for NAG excretion, pentosidine excretion and AGE fluorescence lost the predictive association with macroalbuminuria and microalbuminuria, respectively.

Limitations

Use of angiotensin-converting enzyme inhibitors was not directly ascertained, although their use was proscribed during the DCCT.

Conclusions

Early in type 1 diabetes, repeated measurements of AER and urinary NAG excretion may identify individuals susceptible to future diabetic nephropathy. Combining the 2 markers may yield a better predictive model than either one alone. Renal tubule stress may be more severe, reflecting abnormal renal tubule processing of AGE-modified proteins, in individuals susceptible to diabetic nephropathy.

Index Words: Diabetic nephropathy, advanced glycosylation end products, N-acetyl-β-d-glucosaminidase, albuminuria

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Originally published online as doi:10.1053/j.ajkd.2009.11.009 on February 8, 2010.

PII: S0272-6386(09)01568-6

doi:10.1053/j.ajkd.2009.11.009

Refers to article:

  • Urinary Tubular Biomarkers of Kidney Damage: Potential Value in Clinical Practice

    Femke Waanders, Gerjan Navis, Harry van Goor
    American Journal of Kidney Diseases May 2010 (Vol. 55, Issue 5, Pages 813-816)

American Journal of Kidney Diseases
Volume 55, Issue 5 , Pages 824-834, May 2010